医学
吞咽困难
系统性红斑狼疮
红斑狼疮
肿瘤坏死因子α
免疫学
病理
英夫利昔单抗
吞咽
皮肤病科
胃肠病学
结缔组织病
结节病
水肿
溃疡性结肠炎
并发症
免疫病理学
巨噬细胞活化综合征
炎症
巨噬细胞
内科学
胃肠道
自身免疫性疾病
多发性肌炎
作者
Makoto Misaki,Toshiaki Shimizu,Reo Yamazato,Yuichi Suwa,Yoichi Yasunaga,Keishi Fujio
摘要
Drug-induced lupus erythematosus is an autoimmune condition that resembles systemic lupus erythematosus and occurs after exposure to specific medications, including tumour necrosis factor alpha inhibitors. We report a rare case of golimumab-induced lupus erythematosus complicated by macrophage activation syndrome, angioedema, and severe dysphagia with anti-galactocerebroside antibodies detected. A 57-year-old woman with ulcerative colitis developed facial swelling, malar rash, arthritis, pancytopenia, hyperferritinaemia, hypocomplementaemia, and proteinuria after long-term treatment with tumour necrosis factor alpha inhibitors, most recently golimumab. Bone marrow examination demonstrated haemophagocytosis, confirming macrophage activation syndrome. Computed tomography and endoscopy revealed soft tissue and oesophageal oedema consistent with angioedema. Despite improvement of systemic inflammation following high-dose glucocorticoids and intravenous cyclophosphamide, severe dysphagia persisted. A videofluoroscopic swallowing study demonstrated pharyngeal muscle dysfunction, and serum testing detected anti-galactocerebroside immunoglobulin G antibodies. Neurological imaging and electrophysiological studies were unremarkable. Swallowing function gradually recovered after discontinuation of golimumab. This case highlights that golimumab-induced lupus erythematosus may trigger multiple autoimmune complications, including macrophage activation syndrome, angioedema, and antibody-associated neuromuscular dysphagia. Awareness of these potentially life-threatening manifestations is essential for early recognition and appropriate management in patients receiving tumour necrosis factor alpha inhibitors.
科研通智能强力驱动
Strongly Powered by AbleSci AI